Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects

Jing Xu, Shanaka Stanislaus, Narumol Chinookoswong, Yvonne Y. Lau, Todd Hager, Jennifer Patel, Hongfei Ge, Jen Weiszmann, Shu-Chen Lu, Melissa Graham, Jim Busby, Randy Hecht, Yue-Sheng Li, Yang Li, Richard Lindberg, and Murielle M. Véniant

Departments of 1Metabolic Disorders, 2Pharmacokinetics and Drug Metabolism, and 3Protein Sciences, Amgen Inc., Thousand Oaks; and 4Amgen Inc., South San Francisco, California

Submitted 29 May 2009; accepted in final form 17 August 2009

Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297: E1105–E1114, 2009. First published August 25, 2009; doi:10.1152/ajpendo.00348.2009.—Recombinant fibroblast growth factor (FGF)21 has antihyperglycemic, antihyperlipidemic, and antioesity effects in diabetic rodent and monkey models. Previous studies were confined to measuring steady-state effects of FGF21 following subchronic or chronic administration. The present study focuses on the kinetics of biological actions of FGF21 following a single injection and on the associated physiological and cellular mechanisms underlying FGF21 actions. We show that FGF21 resulted in rapid decline of blood glucose levels and immediate improvement of glucose tolerance and insulin sensitivity in two animal models of insulin resistance (ob/ob and DIO mice). In ob/ob mice, FGF21 led to a 40–60% decrease in blood glucose, insulin, and aminol levels within 1 h after injection, and the maximal effects were sustained for more than 6 h despite the 1- to 2-h half-life of FGF21. In DIO mice, FGF21 reduced fasting blood glucose and insulin levels and improved glucose tolerance and insulin sensitivity within 3 h of treatment. The acute improvement of glucose metabolism was associated with a 30% reduction of hepatic glucose production and an increase in peripheral glucose turnover. FGF21 appeared to have no direct effect on ex vivo pancreatic islet insulin or glucagon secretion. However, it rapidly induced typical FGF signaling in liver and adipose tissues and in several hepatoma-derived cell lines and differentiated adipocytes. FGF21 was able to inhibit glucose release from H4IIE hepatoma cells and stimulate glucose uptake in 3T3-L1 adipocytes. We conclude that the acute glucose-lowering and insulin-sensitizing effects of FGF21 are potentially associated with its metabolic actions in liver and adipose tissues.

TYPE 2 DIABETES HAS BECOME an increasing health concern due to its growing incidence worldwide and its serious consequences in morbidity, mortality, and cost to the health care system (24). Recently, fibroblast growth factor 21 (FGF21) has been evaluated as a potential treatment for type 2 diabetes (3, 10). FGF21 is one of the 22 members of the FGF superfamily (7). Although the majority of the FGF family members are mitogens that stimulate cell proliferation and differentiation, FGF21 lacks mitogenic activity and plays an important role in the regulation of glucose, lipid, and energy homeostasis (2, 5, 11, 21). FGF21 is predominantly expressed in organs related to metabolism, such as liver and pancreas, and is secreted into the bloodstream (5, 16). The expression and circulating levels of FGF21 are subject to nutritional regulation and are elevated during fasting (6). On the basis of in vitro characterizations, FGF21 acts through a signaling receptor complex composed of the coreceptor βklotho and a tyrosine kinase FGF receptor (9, 17, 26). The activity of FGF21 has been shown to stimulate GLUT1 expression and increase GLUT1-mediated glucose uptake in adipocytes (11). FGF21 has also been shown to affect lipolysis in adipose tissues (1, 6), inhibit fatty acid and triglyceride synthesis in liver (25), and preserve β-cell mass and restore β-cell function in the pancreas (22).

Pharmacological studies with recombinant FGF21 have been conducted in a variety of rodent and primate models, including ob/ob, db/db, and diet-induced obese (DIO) mice, ZDF rats, and diabetic rhesus monkeys (11, 12, 25). Systemic administration of FGF21 resulted in striking improvement in metabolic parameters, including sustained decreases in circulating glucose and lipid levels and improvement of glucose tolerance and insulin sensitivity (11, 12, 25). Moreover, FGF21 also modulated energy metabolism by increasing energy expenditure and therefore reversed obesity and hepatosteatosis (25). Results from recombinant protein studies were generally in agreement with the phenotypes of FGF21-transgenic mice (11). Mice that overexpressed FGF21 were lean and protected from age-associated or diet-induced obesity and insulin resistance.

Despite well-established metabolic actions of FGF21, previous studies were all confined to measuring the steady-state effects of FGF21 after subchronic or chronic administration of recombinant FGF21 protein or after transgenic overexpression throughout the development. Limited information is available on the kinetics of the biological actions of FGF21. Therefore, the current study investigates the onset, conclusion, and temporal relationships of the biological effects of FGF21 following a single injection. We also examined the physiological and cellular mechanism underlying the observed effects. Two animal models of insulin resistance, (ob/ob and DIO mice), were used to determine the metabolic effects of FGF21 after a single injection. In addition, the potential cellular mechanism was also explored ex vivo or in cultured cells.

MATERIALS AND METHODS

Preparation of recombinant human FGF21. Recombinant human FGF21 (amino acids 29–209 without signal peptide) was prepared as
previously described (26). Briefly, recombinant human FGF21 was expressed in *Escherichia coli*. It was then folded in solubilized inclusion bodies and purified by ion exchange and hydrophobic interaction chromatography to obtain >90% purity.

**Pharmacokinetics of FGF21 in mice.** FGF21 was administered to male C57BL/6 mice as a single intravenous (iv) administration of 0.1, 0.5, 1, 2, 3, 4, and 6 mg/kg and as a single subcutaneous (sc) or intraperitoneal (ip) administration of 1 mg/kg. Blood samples were obtained at time 0 (predose), 0.1, 0.25, 0.5, 1, 2, 3, 4, and 6 h after administration from each dose group, with three mice per time point for the determination of serum FGF21 levels. Pharmacokinetic parameters were estimated from serum concentration data via a noncompartmental analysis using WinNonlin Professional software (version 4.1c; Pharsight, Mountain View, CA). The initial concentration at time 0 after iv administration (C₀) was estimated by back-extrapolation of the first two observed declining concentration values to time 0. Maximum concentration after sc or ip administration, Cₘₐₓ, and the time maximum concentration occurred (tₘₐₓ) were recorded as observed. Area under the concentration-time curve (AUC) was estimated using the linear/logarithmic trapezoidal method (for the up/down portions of the curve, respectively) up to the last measured concentration that was above the lower detection limit. This area was extrapolated to infinity (AUC₀→∞) by the addition of the last measured concentration divided by the apparent terminal disposition rate constant λ₂, as determined by linear regression analysis of the terminal portion of the log serum concentration-time curve. The terminal half-life (t½,2) was estimated from the terminal rate constant as ln(2)/λ₂.

**FGF21 ELISA assay.** The concentrations of immunoreactive FGF21 in serum samples were determined by a sandwich ELISA developed in house. The murine anti-human FGF21 monoclonal antibodies used as capture and detection reagents were also generated internally. The specificity of the antibodies was verified, and the antibodies were shown to react specifically with human FGF21, with ≥90% purity. The specificity of the antibodies was verified, and the data underwent regression analysis using the Watson (version 7.0.0.01; Thermo Fisher Scientific) data reduction package.

**FGF21 acute metabolic effects in ob/ob mice.** All experiments were approved by the Institutional Animal Care and Use Committee of Amgen, Inc. Male ob/ob mice were ordered from Jackson Laboratories (cat. no. 000632 B6.V-Lep<sup>−/−</sup>; Bar Harbor, Maine) at 6 wk of age. Mice were housed five per cage with free access to drinking water and rodent chow. Mice were allowed to acclimate to a 12:12-h light-dark cycle, housing humidity and temperature, and routine restraints and handling for 2 wk before the initiation of the experiment. On the day of the experiment, blood was sampled from the retroorbital sinus of nonanesthetized mice to measure blood glucose as a baseline value (0 h) with a One Touch Glucometer (LifeScan, Milpitas, CA). Mice were then randomized into vehicle or treatment groups to obtain comparable baseline average blood glucose levels. In the first experiment, vehicle, 10 μg/kg insulin, or FGF21 dose of 1 or 5 mg/kg was ip injected into ob/ob mice. Blood glucose was measured at 1, 3, 6, and 24 h after injection. In a second independent experiment, a broad-range dose-response study for FGF21 was conducted. Vehicle or FGF21 dose of 0.01, 0.1, 1, or 3 mg/kg was ip injected into ob/ob mice. Blood glucose was measured at 3, 6, 9, and 24 h after injection. In a third experiment, an ip glucose tolerance test (IPGTT) was conducted in ob/ob mice. Mice were injected with vehicle or 10 mg/kg FGF21 at 9:00 AM. Blood was removed after injection. The IPGTT was initiated 3 h later with a bolus glucose (50% dextrose; Hospira, NDC) injection at a dose of 2 mg/kg. Blood glucose was measured at 0 (before glucose injection), 30, and 90 min after glucose injection.

In a fourth experiment, plasma insulin, glucagon, and amylin were measured at the same time points when blood glucose levels were determined (1, 3, 6, and 24 h) after a single ip injection of vehicle or FGF21 at 1 or 10 mg/kg. For this purpose, ~75 μl of blood was collected from the retroorbital sinus at each indicated time point. Blood glucose was measured with a One Touch Glucometer, and the rest of the blood samples were centrifuged at 6,000 *g* for 10 min to collect plasma. Plasma insulin, glucagon, and amylin were measured using a mouse endocrine multiplex assay (Linco Research, St. Charles, MO).

**FGF21 acute metabolic effects in DIO mice.** DIO mice were prepared by feeding 4-wk-old male C57BL/6 mice a high-fat diet that contained 60% of energy from fat enriched with saturated fatty acids (D12492; Research Diets, New Brunswick, NJ). After 12 wk of high-fat diet feeding, body weight and blood glucose levels were measured. DIO mice with body weight >40 g and blood glucose level >140 mg/dl were selected and randomized into vehicle or treatment groups to achieve similar baseline average blood glucose levels and body weight between groups.

For the IPGTT experiment, DIO mice were fasted from 9:00 PM to 9:00 AM the next day. Vehicle or 10 mg/kg FGF21 was ip injected at 6:00 AM. Three hours later, an IPGTT was conducted following the same protocol described in the ob/ob section.

An independent 2-h hyperinsulinenic-euglycemic clamp experiment was conducted in DIO mice following a 3-h treatment. Briefly, before (4–5 days) a hyperinsulinenic-euglycemic clamp was performed, mice were anesthetized with an ip injection of ketamine (100 mg/kg body wt) and xylazine (10 mg/kg body wt), and an indwelling catheter was inserted into the right jugular vein, after which the mice were allowed to recover. On the day of the clamp experiment, a three-way connector was attached to the jugular vein catheter for iv delivery of glucose or insulin, and blood samples were obtained from the tail vessels. DIO mice were fasted for 12 h (9:00 PM to 9:00 AM) and injected with vehicle or 10 mg/kg FGF21 at 6:00 AM. Three hours after drug administration (9:00 AM), a hyperinsulinenic-euglycemic clamp was initiated with a primed (150 μl/kg body wt) and continuous infusion of human insulin (Humulin; Eli Lilly, Indianapolis, IN) at a rate of 15 pmol·kg<sup>−1</sup>·min<sup>−1</sup> to raise plasma insulin within a physiological range. Blood samples (20 μl) were collected at 10- to 20-min intervals for the immediate measurement of plasma glucose concentrations, and 20% glucose was infused at variable rates to maintain glucose at basal levels.
concentrations. Basal and insulin-stimulated whole body glucose turnovers were estimated with a continuous infusion of [3-3H]glucose (PerkinElmer Life and Analytical Sciences, Boston, MA) for 2 h before the clamps (0.05 μCi/min) and throughout the clamps (0.1 μCi/min), respectively. All infusions were performed using microdialysis pumps (CMA Microdialysis, North Chelmsford, MA). To estimate insulin-stimulated glucose uptake in individual tissues, 2-deoxy-2-[14C]glucose-6-phosphate content.

Rates of basal hepatic glucose production (HGP) and insulin-stimulated whole body glucose turnover were determined as the ratio of the [3H]glucose infusion rate to the specific activity of plasma glucose at the end of the basal period and during the final 30 min of the clamps, respectively. Insulin-stimulated rates of HGP during the clamp were determined by subtracting the glucose infusion rate from whole body glucose uptake. Whole body glycolysis rates were calculated from the rate of increase in plasma [3H]2O concentration, determined by linear regression of the measurements at 80, 90, 100, 110, and 120 min. Whole body glycogen plus lipid synthesis rates were estimated by subtracting the whole body glycolysis rate from whole body glucose turnover rates. Organ-specific glucose uptake rates were calculated from the plasma 2-[14C]DG decay profile and intracellular 2-[14C]deoxyglucose-6-phosphate content.

Mouse islet isolation and hormone secretion studies. Mouse pancreatic islets were isolated by a modification of the collagenase digestion technique described by Lacy and Kosteniukov (15). Briefly, the abdominal cavity was exposed, the common bile duct was cannulated, and the pancreas was filled with 3 ml of cold digestion buffer composed of Hank’s balanced salt solution (cat. no. 14065-056; Invitrogen, Carlsbad, CA) supplemented with 25 mM HEPES, 100 μg/ml DNase I (cat. no. 10 104 150 001; Roche Diagnostics, Mannheim, Germany) and 0.6 mg/ml collagenase, type XI (cat. no. C7657; Sigma-Aldrich, St. Luis, MO). The distended pancreas was excised, moved to a tube containing 5 ml of digestion buffer, and incubated at 37°C for 12 min. The digest was filtered through gauze and washed three times in Hanks’ balanced salt solution containing 10% fetal bovine serum. Islets were then purified by centrifugation at 1,000 g for 30 min at 4°C on a discontinuous gradient prepared from equal volumes of Histopaque 1.119 g/l and 1.077 g/l (cat. no. 1077-1 and 1119-1, Sigma-Aldrich). Purified islets, which were located at the buffer-Histopaque 1.077 interface, were collected and washed twice in Hanks’ balanced salt solution. The islets were then transferred to RPMI 1640 medium (cat. no. 99-595-CM; Callegro, Manassas, VA) supplemented with 10% fetal bovine serum and 2 mM glutamine and incubated at 37°C for 48 h before secretion studies were performed. For the hormone secretion assay, 10 handpicked, size-matched islets were transferred to 24-well inserts (cat. no. 351184; HTS Multiwell Insert System, Becton-Dickinson, Franklin Lakes, NJ) and incubated for 1 h in oxygenated Krebs-Ringer bicarbonate buffer, pH 7.4, supplemented with 2 mM glutamine, 2 mM arginine, 2 mM alanine, 0.625% human serum albumin, and 1 mM glucose. Islets were then transferred to fresh buffer containing 1 or 10 mM glucose with or without FGF21 (1 μg/ml). After a 1-h incubation at 37°C, islets were removed, and the incubation buffer was used to measure insulin and glucagon contents using the Mouse Endocrine Lincoplex kit (cat. no. MENDO-75K; Millipore, St. Charles, MO).

Cell cultures and adipocyte differentiation. The rat hepatoma cell lines FAO and H4IE, the human hepatoma line HepG2, and 3T3-L1 fibroblasts were obtained from the American Type Culture Collection (Rockville, MD). The FAO cells were maintained in Coon’s modified Ham’s F12 medium supplemented with 10% FBS and 2 mM l-glutamine, and the other cells were maintained in DMEM with the same supplements. 3T3-L1 fibroblasts were induced to differentiation by adding 250 nM dexamethasone (Sigma D4902), 500 mM isobutylmethylxanthine (Sigma I7018), and 1 μg/ml insulin (Sigma I9278) into basic culture medium for 2 days. The cells were then cultured in DMEM with 10% FBS, 1% Pen-Strep, and 1 mg/ml insulin for 2 days and in basic culture medium for an additional 3 days thereafter. Human subcutaneous preadipocytes and postdifferentiated adipocytes were purchased from Zen-Bio (Research Triangle Park, NC) and were maintained in Zen-Bio preadipocyte (cat. no. PM-1) and adipocyte medium (DM-2-500), respectively.

FGF21 signaling, western blot analysis, and ELISA-MSD assay. Cells cultured on multiwell plates were serum starved and treated with recombinant FGF21 at indicated concentrations for 10–15 min. In a study conducted in HepG2 and FAO cells, hepatocellular carcinoma cell line H4IE, and 3T3-L1 adipocytes, treated cells were washed 100 times with PBS and 1% Pen-Strep. FGF21 and FGF23 were used at various concentrations. At the end of the clamp, tissues (gastrocnemius, tibia, epididymal white adipose tissue, heart, and liver) were taken for biochemical analysis as previously described (13).

Glucose production assays in differentiated 3T3-L1 adipocytes. Seven days after differentiation, 3T3-L1 adipocytes were washed once with DMEM containing 1% FBS and 1% Pen-Strep. FGF21 and FGF23 were added to the adipocytes at the indicated concentrations in DMEM with 1% FBS and 1% Pen-Strep, and the adipocytes were incubated for 24 h at 37°C. The cells were then washed once with glucose-free DMEM (Invitrogen 11966-025) containing 0.1% fatty-acid free BSA (Sigma A9205) and FGF21 and FGF23 were added to the cells at the indicated concentrations in the same medium. After 2.5 h of incubation, insulin was added at the indicated concentrations...

Acute metabolic actions of FGF21
Effect of FGF21 was tested in ob/ob glucose tolerance in ob/ob mice. The in vitro potency of FGF21 in a hypoglycemic agent, was included in the same study as a sc dose of 0.1 mg/kg was estimated to be 47.8 and 51.1%, respectively. Similar pharmacokinetics of FGF21 was observed in ob/ob mice (unpublished observation). The predicted binding affinity of FGF21 to one of its receptors, βklotho, and the in vitro potency of FGF21 in a βklotho-recombinant cell line were reported previously (26).

FGF21 acutely reduced blood glucose levels and improved glucose tolerance in ob/ob mice. The acute glucose-lowering effect of FGF21 was tested in ob/ob mice. Insulin, a potent hypoglycemic agent, was included in the same study as a positive control. Vehicle, 10 U/kg insulin, or FGF21 (1 or 5 mg/kg) was injected into 8-wk-old ob/ob mice. Blood glucose was measured before treatment injection and at various time points following the injection. As expected, insulin reduced blood glucose levels by 50% from baseline at 1 h after injection, and the glucose levels returned to baseline 3 h after injection (Fig. 2A). Interestingly, FGF21 also led to a rapid and sustained decrease in blood glucose levels in ob/ob mice. The maximum glucose reduction of 40% from baseline was reached within 1 h after FGF21 injection (Fig. 2A) and was sustained for at least 6 h. The blood glucose levels returned to baseline within 6–24 h (Fig. 2A). The 1 mg/kg dose of FGF21 was a plateau dose, as no further glucose lowering was observed when the FGF21 dose was increased from 1 to 5 mg/kg (Fig. 2A).

A broader dose-response study of FGF21 was subsequently conducted to identify the minimum effective dose. FGF21 was found to be effective in causing a 20–30% glucose drop from baseline at a dose as low as 0.01 mg/kg (Fig. 2B). A dose of 0.1 mg/kg FGF21 led to a maximum glucose reduction of ~60% from baseline in this experiment (Fig. 2B). When the doses were ≥0.1 mg/kg, the glucose-lowering effect of FGF21 was maintained for up to 6 h, then waned between 6 and 9 h, and was finally undetectable at 24 h following injection (Fig. 2, A and B).

An IPGTT was conducted in ob/ob mice to test whether FGF21 could acutely improve the tolerance to a glucose challenge. Vehicle or 10 mg/kg FGF21 was injected into 8-wk-old ob/ob mice. Food was then removed. Three hours later (time 0 of the IPGTT), blood glucose levels were statistically significantly lower in FGF21-treated mice (126 ± 10 mg/dl vs. 166 ± 11 mg/dl in FGF21- vs. vehicle-treated mice, respectively, P < 0.01; Fig. 2C). There was no statistically significant difference in body weight between vehicle and FGF21 treatment groups (data not shown). A bolus glucose solution was injected at time 0. The glucose AUC (data not shown) were statistically significantly reduced in FGF21-treated mice compared with vehicle-treated mice (Fig. 2C).

FGF21 acutely reduced plasma insulin and amylin levels in ob/ob mice. To investigate whether the acute blood glucose-lowering effect of FGF21 was mediated through changes in glucoregulatory hormone levels, we conducted a similar time course study to measure plasma insulin, glucagon, and amylin levels at the same time points for which blood glucose levels were determined (0, 1, 3, 6, and 24 h). For this purpose, a

### Table 1. Mean pharmacokinetic parameters of FGF21 following iv, sc, or ip administration of FGF21 to C57BL/6 mice

<table>
<thead>
<tr>
<th>Pharmacokinetic Parameters</th>
<th>0.1 mg/kg iv</th>
<th>1 mg/kg iv</th>
<th>10 mg/kg iv</th>
<th>1 mg/kg sc</th>
<th>1 mg/kg ip</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>t_{max}, h</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>2.0</td>
<td>0.1</td>
</tr>
<tr>
<td>C_{0} or C_{max}, nM</td>
<td>237</td>
<td>1,890</td>
<td>17,200</td>
<td>73.0</td>
<td>77.0</td>
</tr>
<tr>
<td>AUC_{0-infinity}, h·nm</td>
<td>31.8</td>
<td>443</td>
<td>4,400</td>
<td>187</td>
<td>200</td>
</tr>
<tr>
<td>t_{1/2, z}, h</td>
<td>1.94</td>
<td>1.50</td>
<td>1.45</td>
<td>1.06</td>
<td>1.30</td>
</tr>
<tr>
<td>F, %</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>47.8</td>
<td>51.1</td>
</tr>
</tbody>
</table>

All data presented are means of 3 mice per group. FGF, fibroblast growth factor; NA: not applicable; C_{0}, extrapolated serum concentration at time 0; C_{max}, maximum serum concentration after sc or ip administration; AUC_{0-infinity} area under the concentration-time curve from zero to infinity; t_{1/2, z}, half-life associated with the terminal phase; F, %, bioavailability, relative to mean AUC_{0-infinity} of iv dose group.
relatively large volume (~75 µl) of blood was serially collected from each mouse from the retroorbital sinus at each indicated time point. Similarly to what is shown in Fig. 2, FGF21 at 1 and 10 mg/kg resulted in a rapid and sustained reduction of blood glucose levels in ob/ob mice (data not shown). Interestingly, FGF21 also resulted in a rapid and sustained reduction of plasma insulin and amylin levels, and the temporal change of plasma insulin and amylin levels not only mirrored each other but also paralleled that of blood glucose levels (Fig. 3, A and B). The maximum reduction of insulin and amylin levels from baseline was 40–50%, which was also observed at 1 h following injection and sustained for more than 6 h at the 10 mg/kg dose of FGF21. Plasma glucagon levels were not significantly affected by FGF21 treatment (Fig. 3C). At 1 h after injection, plasma insulin and amylin levels in vehicle-treated mice also significantly declined from baseline, and the treatment difference in insulin levels at 1 h did not reach statistical significance (Fig. 3, A and B). The decrease in plasma insulin and amylin levels at 1 h in vehicle-treated mice may be explained by a stress response induced from frequent animal handling at baseline when animals were injected and blood was collected. Therefore, the current blood sampling technique may not have been ideal. More sophisticated techniques that allow frequent blood sam-

Fig. 2. FGF21 rapidly reduced blood glucose levels and improved glucose tolerance in ob/ob mice. A: time course of FGF21 and insulin on blood glucose lowering over a 24-h period following a single injection in ob/ob mice. Vehicle; □, 1 mg/kg FGF21; ▼, 5 mg/kg FGF21; ■, 10 U/kg insulin. B: dose-response of FGF21 on blood glucose lowering over a 24-h period following a single injection in ob/ob mice. Vehicle; ●, 0.01 mg/kg FGF21; ○, 0.1 mg/kg FGF21; ■, 1 mg/kg FGF21; ▲, 3 mg/kg FGF21. C: ip glucose tolerance test (IPGTT) in ob/ob mice. Mice were ip injected with vehicle or 10 mg/kg FGF21, food was then removed, and IPGTT was initiated 3 h after injection. Data represent means ± SE; n = 8–10 animals/group. *P < 0.001, #P < 0.01, ^P < 0.05 vs. vehicle-treated mice.

Fig. 3. Effects of FGF21 on plasma hormone levels and islet hormone secretion. A–C: following a single injection, FGF21 rapidly reduced plasma insulin (A) and amylin levels (B) without affecting plasma glucagon levels (C) in ob/ob mice. Vehicle; ●, 1 mg/kg FGF21; ○, 10 mg/kg FGF21; □, Vehicle. Data represent means ± SE; n = 10–12 animals/group. #P < 0.01, *P < 0.05 vs. vehicle-treated mice. D and E: insulin (D) and glucagon secretion (E) in cultured mouse pancreatic islets. Mouse pancreatic islets were isolated and incubated in 1 or 10 mM glucose in the presence or absence of FGF21 (1 µg/ml). Culture medium was collected after 1-h incubation to determine insulin and glucagon levels. Data are means ± SE of 4 replicates expressed as pg hormone content·islet−1·h−1.
pling will be necessary to monitor hormonal changes in the future.

To investigate whether FGF21 has a direct role on pancreatic islet insulin and glucagon secretion, isolated mouse islets were treated with FGF21 at low and high concentrations of glucose. As expected, 10 mM glucose stimulated insulin secretion (Fig. 3D) and suppressed glucagon secretion (Fig. 3E) in cultured islets. The addition of 1 μg/ml FGF21 had no effect on insulin or glucagon secretion in either high- or low-glucose conditions (Fig. 3, D and E).

FGF21 acutely improved glucose tolerance and insulin sensitivity in DIO mice. We next investigated whether FGF21 could acutely reduce blood glucose and improve glucose metabolism in polygenic obese DIO mice. Similarly to what was observed in ob/ob mice, fasting blood glucose levels were statistically significantly reduced after 3 h of treatment with FGF21 in DIO mice (time 0 of GTT: 148 ± 4 vs. 115 ± 7 mg/dl in vehicle- vs. FGF21-treated mice, respectively, P < 0.01; Fig. 4A). In these same mice, glucose tolerance was also significantly improved. Plasma glucose levels were statistically significantly lower at 30 min (P < 0.05), 90 min (P < 0.01), and 160 min (P < 0.01) after a bolus glucose injection in FGF21-treated mice compared with vehicle-treated mice (Fig. 4A).

Insulin sensitivity was assessed by performing a hyperinsulinemic-euglycemic clamp study in DIO mice following an FGF21 acute (3-h) treatment. The basal and clamp glucose and insulin levels are shown in Table 2. As was observed with ob/ob mice, DIO mice treated with FGF21 for 3 h showed a statistically significant reduction in basal insulin levels (301 ± 33 vs. 116 ± 16 pM in vehicle- vs. FGF21-treated mice, respectively, P < 0.001; Table 2). A slight reduction in basal fasting blood glucose levels was also observed (227 ± 8 vs. 204 ± 11 mg/dl in vehicle- vs. FGF21-treated mice, respectively, P = 0.115; Table 2). However, the difference did not reach statistical significance, possibly due to the restraining and handling procedure before the initiation of the insulin clamp. With the insulin infusion, plasma glucose levels were clamped at similar physiological concentrations between vehicle- and FGF21-treated groups (Table 2; 132 ± 12 mg/dl vs 115 ± 6 mg/dl in vehicle- vs FGF21-treated mice, respectively). The glucose infusion rate required to maintain euglycemia was approximately sixfold higher in FGF21-treated mice than in vehicle-treated mice (Fig. 4B). The basal hepatic glucose production was not altered by acute FGF21 treatment (Fig. 4C). The clamp hepatic glucose production rate was reduced by 32% in FGF21-treated mice, although this change did not
reach statistical significance (Fig. 4D). Whole body glucose turnover was statistically significantly elevated in mice treated with FGF21 compared with vehicle-treated mice (P < 0.01; Fig. 4E). There was no significant treatment-related change in the rate of whole body glycolysis (Fig. 4F) or glycogen/lipid synthesis (Fig. 4G). The [14C]2-DG uptake was measured in insulin-responsive tissues, including white and brown adipose tissues, heart, and skeletal muscle. None of the tissues examined showed statistically significant increases in glucose uptake [Supplemental Fig. 1 (supplemental material is found in the online version at the Journal website)].

FGF21 stimulated typical FGF signaling in liver and white adipose tissues and in several hepatoma-derived cell lines and differentiated adipocytes. FGF21 has been shown to activate signaling cascades downstream of FGF receptors in a klotho-dependent manner in vitro. The FGF21-induced signaling events, such as phosphorylation of ERK1/2, could be observed within 2–3 min of treatment and peaked at 10 min when tested in multiple cell types, such as INS-1E β-cell line (22) and 3T3-L1 adipocytes (11). To determine which tissues potentially respond to FGF21 stimulation, we examined the tissue expression pattern of klotho and the phosphorylation of signaling molecules downstream of FGF receptors following an acute FGF21 injection in vivo. klotho protein was found to be expressed in liver and adipose tissues and was not detectable in heart and skeletal muscle (Fig. 5A). Consistent with the klotho tissue expression pattern, the typical FGF signaling indicated by the phosphorylation of ERK1/2 was specifically enhanced in liver and adipose tissues 15 min following FGF21 treatment, as shown by Western blot analysis (Fig. 5B). In contrast, the phosphorylation of ERK1/2 was not significantly altered in heart and skeletal muscle (Fig. 5B). An ELISA-MSD assay was independently conducted to quantify phosphorylated and total ERK1/2 in the tissue lysates. FGF21 increased the percentage of phosphorylated ERK1/2 over total ERK1/2 two- to threefold in liver and adipose tissues (Fig. 5C). An ELISA-MSD assay was also conducted to measure phosphorylated and total Akt in response to FGF21 stimulation. FGF21 had minimal effects on Akt phosphorylation in any of the tissues examined (Fig. 5D). Insulin was included in the same experiment to compare its signal transduction profile with that of FGF21. As expected, insulin was a weak activator of ERK1/2 but a strong activator of Akt (Fig. 5, B–D). Insulin had minimal effects on ERK1/2 phosphorylation in liver and heart (Fig. 5, B and C). It primarily stimulated phosphorylation of ERK1/2 in muscle (Fig. 5, B and C), with an intermediate effect in white adipose tissue (Fig. 5B). Insulin strongly induced Akt phosphorylation in all the tissues examined (Fig. 5D). Therefore, FGF21 and insulin induced different intracellular signaling responses in different tissues, suggesting that the two pathways are distinct from each other, at least upstream of the Akt and ERK1/2 targets.

We next examined whether FGF21 could also induce signaling events in adipocytes and liver-derived cell lines. As previously seen in published results regarding 3T3-L1 adipocytes (11, 17), FGF21 stimulated phosphorylation of FRS-2 and ERK1/2 in human differentiated adipocytes (Fig. 6A). The signaling activity was not detectable in undifferentiated human

Fig. 5. FGF21 stimulated phosphorylation of ERK1/2 specifically in liver and adipose tissues in C57BL6 mice. A: Western blot analysis of klotho tissue expression in C57B6 mice. Total tissue lysates were prepared and pooled from 4 mice and subjected to Western blot analysis. B: C57B6 mice were injected ip with vehicle, 50 U/kg insulin, or 10 mg/kg FGF21. Liver, white adipose tissue (WAT), heart, and skeletal muscle tissues were collected 15 min following injection. Total tissue lysates were prepared and pooled from 3 mice for Western blot analysis. p-Erk, phosphorylated ERK. C and D: ELISA-MSD assay for p-ERK1/2 and total ERK1/2 (C) and p-Akt and total Akt (D). Tissue lysates were subjected to ELISA-MSD assays. Data are expressed as percentage of p-ERK1/2 or p-Akt relative to total ERK1/2 or Akt. Open bar, vehicle; gray bar, 50 U/kg insulin; filled bar, 10 mg/kg FGF21. Data are means ± SE; n = 3 per group.
preadipocytes (Fig. 6A), possibly due to the lack of βklotho expression in preadipocytes. We also confirmed the previous finding that FGF21 dose-dependently stimulated phosphorylation of ERK1/2 in 3T3-L1 adipocytes but not in human predifferentiated adipocytes. Cells were starved overnight and then treated with or without 250 nM FGF21 for 10 min. Total cell lysates were prepared and subjected to Western blot analysis. B: dose-response of FGF21 on ERK1/2 phosphorylation in differentiated 3T3-L1 adipocytes. C: FGF21 (20 nM) stimulated phosphorylation of FRS2 and ERK1/2 in H4IE rat hepatoma-derived cells. D: FGF21 stimulated phosphorylation of FRS2 in HepG2 and FAO hepatoma-derived cell lines. Cells were treated with or without 30 nM FGF21 in the presence or absence of 1 μg/ml heparin for 10 min.

Fig. 7. FGF21 dose-dependently decreased glucose production in H4IE cells and stimulated glucose uptake in 3T3-L1 adipocytes. H4IE hepatoma-derived cells have many properties similar to those of hepatocytes and have been broadly used as a cellular system to study glucose metabolism and insulin signaling. We tested whether FGF21 could affect glucose production in H4IE cells. Insulin was used as a positive control. As expected, insulin showed strong inhibition of glucose production with an IC_{50} value of ~60 pM (Fig. 7A). Treatment with FGF21 also resulted in a dose-dependent reduction of endogenous glucose production in H4IE cells, with an IC_{50} value of ~0.8 nM (Fig. 7B). We also conducted a dose-response study to evaluate the potency of FGF21 in stimulation of glucose uptake in differentiated 3T3-L1 adipocytes. As expected, insulin used as a positive control showed stimulation of glucose uptake in adipocytes, with an EC_{50} value of ~1.0 nM (Fig. 7C). FGF23, a close family member of

![Figures A to E showing dose-response curves](http://ajpendo.physiology.org/)

**Fig. 6.** FGF21 stimulated typical FGF signaling in differentiated adipocytes and hepatoma-derived cell lines. A: FGF21 increased phosphorylation of FGF receptor substrate 2 (FRS2) and ERK1/2 in differentiated human sc adipocytes but not in human predifferentiated adipocytes. Cells were starved overnight and then treated with or without 250 nM FGF21 for 10 min. Total cell lysates were prepared and subjected to Western blot analysis. B: dose-response of FGF21 on ERK1/2 phosphorylation in differentiated 3T3-L1 adipocytes. C: FGF21 (20 nM) stimulated phosphorylation of FRS2 and ERK1/2 in H4IE rat hepatoma-derived cells. D: FGF21 stimulated phosphorylation of FRS2 in HepG2 and FAO hepatoma-derived cell lines. Cells were treated with or without 30 nM FGF21 in the presence or absence of 1 μg/ml heparin for 10 min.
FGF21, did not show the ability to stimulate glucose uptake in adipocytes (Fig. 7D), whereas FGF21 increased adipocyte glucose uptake, with an EC$_{50}$ value of $\sim$1.5 nM (Fig. 7E).

**DISCUSSION**

Despite abundant information relating to the steady-state metabolic effects of FGF21 following subchronic or chronic administration of FGF21 in animal models, limited knowledge is available on the kinetics of the biological action of FGF21 and the associated physiological and cellular mechanisms. Here, we show that FGF21 rapidly reduced blood glucose and insulin levels and improved glucose tolerance and insulin sensitivity in two separate insulin-resistant animal models (ob/ob and DIO mice). FGF21 appeared to have no direct effect on pancreatic islet insulin or glucagon secretion. The rapid onset of glucose-lowering and insulin-sensitizing effects was associated with an immediate induction of typical FGF signaling in liver and adipose tissues and was accompanied by a reduction of hepatic glucose production and an increase in peripheral glucose turnover. The potential metabolic actions of FGF21, such as suppression of hepatic glucose production and stimulation of adipocyte glucose uptake, may have contributed to the observed FGF21 effects.

In ob/ob mice, a single dose of FGF21 resulted in a 40–60% decrease in blood glucose, insulin, and amylin levels within 1 h after administration. In DIO mice, FGF21 decreased fasting blood glucose and insulin levels and improved glucose tolerance and insulin sensitivity following a 3-h treatment. Although studies from another laboratory suggest that reduced glucagon secretion may be one of the mechanisms responsible for the antihyperglycemic effect of FGF21 (11), we have not been able to detect FGF21 inhibition of glucagon secretion ex vivo or to observe changes in plasma glucagon levels following FGF21 administration in the previous chronic (25) or current acute studies. We were, however, able to consistently observe a marked reduction in plasma insulin levels following FGF21 injection. In the current study, plasma insulin levels were reduced as quickly as 1 h after FGF21 injection, and the temporal change of plasma insulin levels paralleled that of blood glucose levels. Our data suggest that FGF21 is an insulin sensitizer and that its acute glucose-lowering effect is not mediated through stimulating insulin or suppressing glucagon secretion.

The reduction in insulin levels could result from either a decrease in insulin secretion or an increase in insulin clearance through hepatic extraction or a combination of both. To provide insights into which mechanism was predominant, we measured plasma concentration of amylin, a pancreatic hormone that is cosecreted with insulin from islets with negligible hepatic extraction (8, 20). Plasma amylin levels were reduced to a similar extent and followed a similar time course to that of plasma insulin, suggesting that insulin secretion rather than insulin clearance was largely altered by FGF21 treatment. FGF21 did not appear to have a direct role in inhibiting insulin release when tested in cultured mouse islets. A similar observation was reported in a previous publication from another research group, indicating that FGF21 had a minimal effect on insulin secretion from rat islets although it affected insulin biosynthesis (22). Therefore, the decrease in plasma insulin levels observed in our study likely resulted from improved peripheral tissue insulin sensitivity and subsequently reduced $\beta$-cell compensation. It is yet to be determined what signals communicated from the peripheral tissues to the pancreatic $\beta$-cells. Glucose is known as a dominant regulator of insulin release, and a decrease in plasma glucose concentration has been shown to have an immediate inhibitory effect on insulin secretion (4, 18). Therefore, the reduced insulin secretion was likely due to $\beta$-cell sensing of a reduction in blood glucose levels after FGF21 treatment.

The acute improvement in insulin sensitivity was confirmed by a hyperinsulinemic-euglycemic clamp study conducted in DIO mice following a 3-h FGF21 treatment. The glucose infusion rate was increased sixfold in association with a 32% reduction in hepatic glucose production and a 20% increase in whole body glucose turnover. However, when we examined the $[^{14}\text{C}]$ 2-DG uptake in insulin-responsive tissues, including white and brown adipose tissues, heart, and skeletal muscle, none of the tissues tested showed statistically significant increases in glucose uptake. It is possible that the assay sensitivity was not sufficient to detect individual tissue responses to an overall modest change in the total glucose turnover rate (20%). Nevertheless, results of the present acute study are consistent with results from our previous 3-wk chronic study conducted in the same animal model with the same 10 mg/kg$^{-1}$·day$^{-1}$ FGF21 dose (25). In that chronic study, FGF21 increased the glucose infusion rate 30-fold, which was accompanied by an 80% reduction in clamp hepatic glucose production and a 40% increase in whole body glucose turnover. We observed increased glucose uptake in all the tested tissues, including adipose tissue, muscle, and heart. The enhanced effects in the chronic study could be attributed to the subsequent reduction in body weight, body fat mass, and lipid levels in plasma and tissues, which did not occur in our acute paradigm.

FGF21 initiates its action by activating FGF receptors in the presence of a coreceptor, $\beta$klotho (17, 26). We were able to detect protein expression of $\beta$klotho in liver and adipose tissues but not in skeletal muscle or heart tissues. In agreement with the $\beta$klotho tissue expression pattern, following a single injection, FGF21 induced phosphorylation of ERK1/2 in liver and adipose tissues but not in skeletal muscle or heart. The FGF21-stimulated signaling cascades, including FRS2 and ERK1/2 phosphorylation, were also detected in multiple hepatoma-derived cell lines and in differentiated human and mouse adipocytes. The rapid signaling events observed in liver and adipose tissues and the lack of a direct effect on pancreatic islet insulin and glucagon secretion suggest that the acute glucose-lowering and insulin-sensitizing effects of FGF21 may result from its metabolic actions in peripheral tissues such as liver and adipose tissues. FGF21 was able to reduce glucose production in our experiments with H4IIE cells. We also confirmed that FGF21 stimulated glucose uptake in 3T3-L1 adipocytes (11). The typical EC$_{50}$ of FGF21 in these assays was $\sim$1 nM, which was consistent with the observed FGF21 concentrations for which the blood glucose-lowering effects were seen. Therefore, our data suggest that the metabolic actions of FGF21 on liver or adipose tissues may contribute to its glucose-lowering and insulin-sensitizing effects.

The rapid and sustained in vivo pharmacodynamic characteristics of FGF21 suggest that a variety of cellular processes may be involved in the mechanisms of FGF21 action. Unlike peroxisome proliferator-activated receptor-γ agonist and metformin, which
produce insulin-sensitizing effects rather slowly because of transcriptionally mediated mechanisms (19, 23). FGF21 led to rapid insulin sensitization within 1 h. Such acute effects (<1 h) may be mediated through posttranslational events without the requirement of new protein synthesis through modulation of metabolic enzyme activities through kinase- and phosphatase-mediated reactions. Whether FGF21 signaling could functionally replace insulin signaling or whether these two pathways cross-talk in the regulation of glucose metabolism requires further studies in the future. The prolonged effect of FGF21 may be mediated through gene transcript and protein synthesis. FGF21 activates the ERK pathway, which is known to regulate the activities of transcription factors and alter transcription of the genes (14). FGF21 has been shown to increase GLUT1 mRNA expression, which leads to increased glucose uptake in 3T3-L1 adipocytes (11). This has been suggested as a transcription-mediated mechanism, because the glucose uptake was abolished when the protein synthesis inhibitors were added into the culture medium (11). In addition, we also demonstrated that FGF21 has the ability to regulate lipogenic gene expression by reducing the nuclear content of transcription factor sterol regulatory element binding protein-1 (25). Overall, FGF21 may control its activities through a diverse mechanism involving posttranslational and transcriptional regulation.

In conclusion, administration of FGF21 elicited rapid and sustained metabolic effects on lowering blood glucose and improving glucose tolerance and insulin sensitivity in two animal models of insulin resistance. The improved glucose metabolism and insulin sensitivity were possibly associated with the metabolic effects of FGF21 in liver and adipose tissues. The present acute study and our previously published chronic study (25) highlight the importance of FGF21 action on glucose-lowering and insulin sensitization.

ACKNOWLEDGMENTS

We thank Larissa Atanqan and Christina Abbott for technical support. We thank Scott Silbiger for editorial support for the manuscript.

DISCLOSURES

All authors are Amgen Inc. employees, and the studies were supported by Amgen, Inc.

REFERENCES